Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results